Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
September 20, 2021 Cover
Volume 99, Issue 34
A new class of therapies based on transfer RNA could treat forms of cystic fibrosis, muscular dystrophy, genetic epilepsies, and more
Cover image:A new class of therapies based on transfer RNA could help restore protein production in forms of cystic fibrosis, muscular dystrophy, genetic epilepsies, and other diseases that have proved hard to treat with gene editing and gene therapy
Credit: William Ludwig/C&EN/Shutterstock
tRNA therapies could help restore proteins lost in translation
A new class of therapies based on transfer RNA could treat forms of cystic fibrosis, muscular dystrophy, genetic epilepsies, and more
Climate change could alter undersea chemical communication
A changing climate may tamper with marine animals’ sense of smell and change the shapes of signaling molecules
The biodegradable polymer PBAT is hitting the big time
Polybutylene adipate co-terephthalate is succeeding by straddling the peterochemical and biopolymer worlds
-
Want a promotion? Chemjobber says to take the initiative now
Changes in the job market offer a chance to be the boss
-
Oligonucleotide synthesis gets an overhaul
Phosphorus(V) chemistry connects nucleosides for therapeutic applications
-
ADVERTISEMENT
Science Concentrates
Oligonucleotide synthesis gets an overhaul
Phosphorus(V) chemistry connects nucleosides for therapeutic applications
Business & Policy Concentrates
- DSM eyes exit from traditional chemical sector
- Solugen raises $357 million for its ‘chemienzymatic’ approach
- Formosa to pay $2.85 milllion in penalties plus follow new safety requirements
- What we need to know to address PFAS contamination
- Another HIV vaccine fails, highlighting long-standing challenges in the field
ADVERTISEMENT
ACS NEWS
OBITUARIES
- Obituary: Gerald Stanley Brenner
- Obituary: Norman C. Craig
- Obituary: James E. Kurz
- Obituary: Maria O. Longas
- Obituary: Barbara Bursa Martin
- Obituary: Robert Harris Maybury
- Obituary: Robert A. Newton
- Obituary: Mark W. Orme
- Obituary: Jack Peisach
- Obituary: Willard Monroe St. John Jr.
